MALT lymphoma · 11 regimens
Cost vs Efficacy · 6 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Fludarabine and Rituximab (FR) Variant #06 | — | R 117 749 | 28d | — | — | — | — | — |
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | ~39.4 mo | — | ~35 | ~R 3 036 103 PFS proxy · indirect | 5 |
Cladribine monotherapy Variant #01 | — | R 59 905 | 5d | — | — | — | — | — |
Bendamustine and Rituximab (BR) Variant #12 | — | R 40 807 | 28d | ~39.6 mo | — | ~44 | ~R 1 795 506 PFS proxy · indirect | 18 |
Cladribine and Rituximab Variant #01 | — | R 33 968 | 21d | — | — | — | — | — |
Chlorambucil and Rituximab (RClb) Variant #03 | — | R 28 365 | 28d | — | — | — | — | 1 |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
MCP Variant #01 | — | R 6 506 | 28d | — | — | — | — | — |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~30.8 mo | — | ~11 | ~R 69 973 PFS proxy · indirect | 2 |
Chlorambucil monotherapy Variant #12 | — | R 2 523 | 14d | ~12.6 mo | ~69.7 mo | ~28 | ~R 70 639 PFS proxy · indirect | 6 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 17 |
11 of 11 regimens shown